Background: Systemic allergic reactions are a risk for allergen immunotherapy that
| INTRODUCTION
Conventional allergen injection immunotherapy, based on the concept of tolerance induction, 1, 2 involves the administration of incremental doses of the sensitizing allergen followed by monthly highdose maintenance injections for several years. 3 This paradigm, which is the basis for a personalized medicine approach using "named patient products" that are still common in the United
States and in parts of Europe, has been shattered during recent years. Regulatory agencies, such as the German Paul-Ehrlich-Institut and the European Medicines Agency, regard allergen preparations as therapeutics similar to synthesized molecules and recommend a classical product development pathway. 4 This concept requires evidence of an optimal therapeutic dose, which is defined within the framework of efficacy, tolerability and safety. In this regard, the standard procedures of developing medicines also have to be applied to immunotherapeutics containing the prevalent allergens of the homologous groups of trees, grasses and house dust mites. 5 After preclinical tests assuring quality and harmlessness in terms of toxicology, the 3 classical phases of the product development route apply.
Lolium perenne peptides immunotherapy has been shown to have limited IgE binding, basophil and mast cell reactivity and hence is considered as a safe alternative that can be administered at higher doses and for a shorter period to improve treatment adherence. 6 Here, we report a proof-of-concept study, which involved an up-dosing regimen with the primary aim to assess safety and to identify an individual maximum tolerated cumulative dose for patients with different statuses of allergen sensitization.
Furthermore, we investigated the immunological effects and a surrogate parameter of clinical efficacy. 
| Study design
This open-label, prospective, dose-escalation study was performed in grass pollen-allergic patients outside of the grass pollen season.
Patients were required to give written informed consent before being included in the study. Participants were required to have a medical history of moderate-to-severe seasonal allergic rhinoconjunctivitis during the grass pollen seasons of at least the 2 previous years. In addition, a positive skin prick test (wheal diameter ≥3 mm for a grass pollen mixture) and grass pollen-specific IgE (sIgE)
antibodies >0.7 kU/L were necessary for study inclusion (see Data S1 for further inclusion and exclusion criteria).
The study was carried out in the outpatient allergy clinic of the Department of Oto-Rhino-Laryngology at the University Hospital
Carl-Gustav-Carus (Dresden, Germany) and consisted of 8 visits: 1 screening visit (V1), 6-weekly treatment visits (V2-V7) and 1 followup visit (V8), which took place 1-2 weeks after V7. The patients received 12 subcutaneous injections of increasing doses of LPP in form of a cluster scheme. 9 At each treatment visit (V2-V7), 2 injections of equal peptide dose were administered 30 minutes apart, one in each arm. After the second injection, patients remained under observation at the trial site for a further 30 minutes. Dose escalation started with a total LPP dose of 10 lg administered at V2 and increased to 20 lg at V3, 40 lg at V4, 80 lg at V5, 140 lg at V6
and 200 lg at V7, resulting in a cumulative dose of 490 lg.
| Formulation of the Lolium perenne peptides (LPP)
Based on the extensive immunological cross-reactivity among grass pollens belonging to different species, Lolium perenne (L. perenne)-derived allergens are considered appropriate for the treatment of IgE-mediated grass pollen allergy in general. 10 Briefly, L. perenne proteins were extracted from a natural source to obtain a crude extract, which was then purified of nonprotein components. The proteins were then denatured and enzymatically hydrolysed to generate peptides of 1000-10 000 Da. 6 The LPP were supplied in ready-to-use vials with a ryegrass pollen peptide concentration of 100 lg/mL in 1.5 mL aqueous-buffered solution (pH 7.4). The formulation contained no adjuvant. 2.5 | Reactivity to the conjunctival provocation test
As a secondary endpoint, the CPT was used as a surrogate marker for the assessment of the clinical effects of the LPP treatment. The
CPT was performed at V1, V6 and V8 using the allergen extract ALK-lyophilized SQ (ALK-Abell o, Hamburg, Germany) with standardized units (SQ-E/mL). 12 The stock solution consisted of 100 000 SQ-E/mL and was extemporaneously diluted to 10 000, 1000 and 100 SQ-E/mL. The test procedure was performed and evaluated according to the CPT protocol described by Riechelmann et al 13 and
was considered positive if the response was stage II or higher. The CPT score was calculated as 0 = no reaction at all, 1 = reaction at 10 000 SQ-E/mL, 2 = reaction at 1000 SQ-E/mL and 3 = reaction at 100 SQ-E/mL.
| Allergen-specific immunoglobulin and blocking antibody production
Specific IgE and IgG 4 levels for 5 grasses (Anthoxanthum odoratum, Lolium perenne, Phleum pratense, Secale cereale and Holcus lanatus)
were measured in serum at V1, V6 and V8 using the ImmunoCap â method (Pharmacia Diagnostics AB, Uppsala, Sweden). The IgGassociated blocking antibodies were measured by FAB assay 10, 14, 15 (see Data S1 for detailed description).
| Statistical analysis
The statistical analysis was performed using IBM SPSS Statistics for were analysed using the Friedman signed rank test, taking into account correction for multiple comparison. A P < .05 was considered providing the statistical significance threshold.
3 | RESULTS
| Demographic data and baseline values
Overall, 88 patients were screened. Of these, 20 patients did not fulfil the inclusion criteria or met at least one of the exclusion criteria, 
| Conjunctival provocation test (CPT)
The clinical effects of LPP were analysed using the surrogate parameter CPT. At baseline, a positive reaction was documented for 19.2% of patients at 100 SQ-E/mL, 53.8% of patients at 1000 SQ-E/mL and 26.9% of patients at 10 000 SQ-E/mL (Figure 2A ). At V6, reactivity to the CPT was lower than that at baseline in 83% of patients. Most of the patients (67.3%) did not react at all to the CPT, and 25.0% of the patients reacted at the 10 000 SQ-E/mL level. At V8, CPT reactivity was decreased compared to baseline in 87.5% of the patients, and 69.8% of patients did not react to provocation at all. Fifteen patients (28.3%) reacted to the highest concentration of 10 000 SQ-E/mL, and only one patient (1.9%) reacted to 1000 SQ-E/mL. None of the patients reacted to 100 SQ-E/mL at V8. The improvement was also reflected by the change in the CPT score ( Figure 2B ). The mean CPT score was significantly lower at V6 (P < .001) and V8 (P < .001) than at V1. These findings are supported by the objective measurements of conjunctival redness using digital image analysis. 16 Figure 3 depicts the reduction in the proportion of red pixels in the region of interest as a sign of decreased conjunctival vasodilation. Table S1 . The most frequently reported AE was injection site pruritus (21.5% of patients).
| Safety
Six patients (9.2%) experienced at least one SR (coded as hypersensitivity in Table S1 
| Immunogenicity
Specific IgE levels to grass pollen were increased at V6 (P < .001) and at V8 (P < .001) compared to V1 ( Figure 4A ) but to a lesser extent than sIgG 4 serum levels (8.0-fold increase at V6 [P < .001] and 12.2-fold increase at V8 [P < .001]) ( Figure 4B ). Consequently, the sIgE:sIgG 4 ratio decreased from V1 to V6 (P < .001) and from V1 to V8 (P < .001) ( Figure 4C ). Treatment with LPP also induced a significant production of specific IgG (P < .001) but had no effect on IgA (data not shown). Serum inhibitory activity for IgE-FAB was assessed using the FAB assay. The values for the mean relative IgEallergen complex binding to B cells were lower at V6 (P < .001) and at V8 (P < .001) than at V1. The absolute decreases for IgE-FAB were 18% (V6) and 25% (V8) ( Figure 5A ). Moreover, the change from baseline in the FAB value was strongly associated with specific IgG 4 at V6 (Spearman rank correlation coefficient: r = .56, P < .001) and V8 (r = .45, P = .001) ( Figure 5B ).
| DISCUSSION
In this study, we show for the first time that the use of hydrolysates of LPP escalated to a maximum cumulative dose of 490 lg was well tolerated (86.9% of the patients reached this target dose), eliciting only minimal early local and late skin responses. There were a few, mostly mild, systemic reactions to these high-dose allergen injections that required either no treatment or responded well to oral antihistamines and, in a single case, inhaled fenoterol. No serious adverse drug reactions, no anaphylactic reactions and no use of epinephrine were reported throughout the study. The overall good safety profile can be explained by the ex vivo characteristics of LPP (limited IgE binding, basophil and mast cell reactivity). 6 There was a marked and consistent reduction in the immediate conjunctival response to whole allergen extract and an increase in functional specific IgG antibodies.
Local reactions at the injection site represent a relevant parameter when addressing the safety of grass pollen SCIT. Thirty minutes after the injections, all mean wheal diameters were mild (below the 5-cm threshold) 17 and transient, highlighting the overall good safety profile of the LPP treatment administered in such a cluster schedule.
Wheals were accompanied by a small area of redness. Mean wheal and redness diameters increased slightly 8 hours after the injection, and a few patients reported moderate/severe local reactions.
Although inconvenient, delayed (6-12 hours) local reactions are not regarded as an increased risk for SRs. 18 The safety and tolerability of the LPP treatment appear to be better than those reported for an ultra-short up-dosing scheme with a 6-grass mix and rye allergen F I G U R E 3 Digital analysis of the percentage of red pixels in the conjunctival region of interest (ROI) in patients undergoing conjunctival allergen challenge before (V1), during (V6) and after (V8) LPP immunotherapy (ITT set). R max is the percentage of red pixels in the ROI following the maximum tolerated allergen concentration.
ITT, intention to treat; LPP, Lolium perenne peptides formulated for subcutaneous injection; RMS, root mean square extract performed in-season. 19 In that study, wheal diameters ranging from 5 to 20 cm (11.9%) and even larger than 20 cm (0.3%)
were observed 30 minutes after injection. The high local reactivity reported by the authors could be explained by the fact that product administration was performed during the pollen season. 20, 21 The analysis of the occurrence of SRs (9.2% of patients and 0.9% of injections, no grade III or grade IV SR) also suggests that LPP has a safety profile comparable to that of conventional SCIT, although a direct comparison is difficult due to differences in study designs and populations. A Cochrane meta-analysis of data on SCIT products used in 51 clinical studies showed that SRs occurred in 19% of patients. 4 . Spearman rank correlation coefficient r = .452, P < .05 was considered significant. Ag, allergen; FAB, facilitated allergen binding; Ig, immunoglobulin; ITT, intention to treat; LPP, Lolium perenne peptides formulated for subcutaneous injection; Phl p, Phleum pratense; SEM, standard error of the mean; V, visit and for 21.2% patients in the 10 000 SQ-U group. Moreover, 9 nonlife-threatening reactions of grade III (according to the EAACI classification) were observed. 24 In a more recent study, 7.1% of the patients experienced SRs following an ultra-short up-dosing schedule with Alutard SQ â up to the maintenance dose of 10 000 SQ-U. 19 SRs were also observed in 5.6% of the placebo group patients. The frequency of SRs reported by these authors is similar to the one observed here with LPP; however, no information on the severity of the SRs can be deduced from their study. 19 As mentioned earlier, SRs occurred in 0.9% of all injections in the present study. This is much lower than the frequency observed with the depot allergoid Purethal â (4.3%) 25 or with other SCIT products (reviewed in Ref 26, 27 ) and similar to the data reported after a conventional administration schedule with a 5-grass recombinant allergen mixture (0.98%).
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Although these data showed an overall good safety profile for LPP, they were obtained in a limited number of patients and need to be confirmed in larger studies.
Besides assessing the safety of LPP treatment, the CPT surrogate marker was used to follow up on the clinical status of the patients.
Conjunctival provocation has been shown to be a reliable method for diagnosing allergy and for evaluating the clinical effect of immunotherapy products, especially if digital image analysis is used. 7, 16 A decrease in CPT reactivity from baseline was observed in 83% (V6) and 87.5% (V8) of patients. In addition, most of the patients (67.3%) no longer reacted at all to the CPT at V6. No further reduction in CPT reactivity was found at V8 (69.8%). The objective assessment of conjunctival vasodilation using digital image analysis was in line with the findings of the investigators. These data are similar to those of Klimek et al, 22 although the studies are not directly comparable due to the different CPT provocation solutions and methodology used.
We acknowledge the limitation of this study due to the lack of a placebo arm. Nonetheless, these results clearly suggest a significant therapeutic effect can be observed after only 4 weeks of treatment and the administration of a cumulative dose of 150 lg of LPP.
As a secondary outcome, the immunological effect of LPP treatment was analysed by measuring sIgE and sIgG 4 levels as well as the production of functional blocking antibodies. Specific IgE increased during the course of the study (1.7-fold). Some studies postulated that an increase in sIgE levels following SCIT might be associated with an increased risk of systemic AEs. 29, 30 With regard to the ratio of SRs to injections and the small (although statistically significant) increase in sIgE levels presented here, the number of SRs was not higher than that reported in other studies. 2, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] As reported previously, 6 we observed a stronger induction of sIgG 4 as early as 4 weeks after the initiation of treatment, with a further increase following treatment completion. This resulted in a shift of the sIgE:sIgG 4 ratio towards the induction of tolerance.
These data, especially the induction of sIgG 4 , concur with those of previous studies investigating conventional and short-course adjuvant-containing SCIT and sublingual immunotherapy. [31] [32] [33] The desirable immunological effects, which are similar to those of conventional long-term SCIT treatment, elucidate the mechanisms of action of LPP. Moreover, to our knowledge, LPP is the first peptide preparation which induces the production of blocking antibodies against allergens as measured by a functional bio-cellular assay. 15 No other studies performed with peptides have demonstrated the induction of protective blocking antibodies following treatment. 34, 35 In summary, the short-course cluster treatment with the adjuvant-free LPP formulation investigated here showed an overall good safety and tolerability profile, with virtually no local pain, discomfort or swelling following injections being reported. LPP also elicited a positive immune effect and a clinical effect in seasonal allergic rhinitis patients. Larger studies are of course needed to confirm the safety and efficacy of cluster treatment with LPP, starting with a randomized, double-bind, placebo-controlled dose-finding study.
However, the favourable data reported here suggest that LPP might lead to improved patient compliance and ultimately to improved efficiency.
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